Journal
PEDIATRIC BLOOD & CANCER
Volume 66, Issue 5, Pages -Publisher
WILEY
DOI: 10.1002/pbc.27595
Keywords
circulating tumor DNA; pediatric cancer; next-generation sequencing; digital PCR; liquid biopsy
Categories
Funding
- Nuovo-Soldati Fundation
- NCI [K08CA188073-03]
Ask authors/readers for more resources
Circulating tumor DNA can be detected in the blood and body fluids of patients using ultrasensitive technologies, which have the potential to improve cancer diagnosis, risk stratification, noninvasive tumor profiling, and tracking of treatment response and disease recurrence. As we begin to apply liquid biopsy strategies in children with cancer, it is important to tailor our efforts to the unique genomic features of these tumors and address the technical and logistical challenges of integrating biomarker testing. This article reviews the literature demonstrating the feasibility of applying liquid biopsy to pediatric solid malignancies and suggests new directions for future studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available